Drug Profile


Alternative Names: Aligrin; Bellozal; Bilador; Bilahist; Bilanoa; Bilaska; Bilaxten; Bilaz; Bilidren; BLEXTEN; Borenar; Clatra; Drynol; F-96221-BM; Fortecal; Gosall; Ibis; Ilaxten; Inorial; Labixten; Lamiastine; Lendin; Lergonix; Nasitop; Nixar; Obalix; Olisir; Omarit; Opexa; Revitelle; Robilas; TAC-202; Vitador; Xados; Zilas

Latest Information Update: 16 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator FAES Farma
  • Developer Aralez Pharmaceuticals Inc.; FAES Farma; Menarini; Taiho Pharmaceutical; Yuhan
  • Class Antiallergics; Benzimidazoles; Piperidines; Small molecules
  • Mechanism of Action Histamine H1 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Allergic conjunctivitis; Perennial allergic rhinitis; Pruritus; Seasonal allergic rhinitis; Urticaria
  • Phase III Allergic rhinoconjunctivitis
  • Discontinued Angioedema

Most Recent Events

  • 11 Oct 2017 Faes Farma completes a phase II trial in Allergic conjunctivitis in USA (Ophthalmic) (NCT03231969)
  • 01 Jul 2017 Phase-II clinical trials in Allergic conjunctivitis in USA (Ophthalmic) (NCT03231969)
  • 19 Dec 2016 Launched for Seasonal allergic rhinitis in Canada (PO) ((9209221)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top